Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

Department of Oncology, Hospital Santa Maria della Misericordia, Sant Andrea delle Fratte, Perugia, Italy.
The Lancet Oncology (Impact Factor: 25.12). 08/2010; 11(8):733-40. DOI: 10.1016/S1470-2045(10)70151-0
Source: PubMed

ABSTRACT Results of two phase 3 trials have shown first-line bevacizumab in combination with chemotherapy improves clinical outcomes in patients with advanced or recurrent non-squamous non-small-cell lung cancer (NSCLC). The SAiL (MO19390) study was undertaken to assess the safety and efficacy of first-line bevacizumab combined with standard chemotherapy regimens in clinical practice.
Between August, 2006, and June, 2008, patients with untreated locally advanced, metastatic, or recurrent non-squamous NSCLC were recruited to this open-label, single group, phase 4 study from centres in 40 countries. Eligible patients had histologically or cytologically documented inoperable, locally advanced, metastatic, or recurrent disease (stage IIIB-IV); an Eastern Cooperative Oncology Group performance status of 0-2; and adequate haematological, hepatic, and renal function. Patients received bevacizumab (7.5 or 15 mg/kg every 3 weeks) plus standard chemotherapy for up to six cycles, followed by single-agent bevacizumab until disease progression. The primary endpoint was safety; analysis was by intention to treat (ITT). This study is registered with, number NCT00451906.
At the final data cutoff (July 24, 2009), an ITT population of 2212 patients was assessed. The incidence of clinically significant (grade > or = 3) adverse events of special interest was generally low; thromboembolism occurred in 172 (8%) patients, hypertension in 125 (6%), bleeding in 80 (4%), proteinuria in 67 (3%), and pulmonary haemorrhage in 15 (1%). 57 (3%) patients died because of these adverse events, with thromboembolism (26 patients, 1%) and bleeding (17, 1%) as the most common causes. The most common grade 3 or higher serious adverse events deemed by investigators to be associated with bevacizumab were pulmonary embolism (28 patients; 1%) and epistaxis, neutropenia, febrile neutropenia, and deep vein thrombosis (all of which occurred in 13 patients [1%]). Bevacizumab was temporarily interrupted after 28 (2%) of 1347 bleeding events and 72 (7%) of 1025 hypertension events, and permanently discontinued after 110 (8%) bleeding events and 40 (4%) hypertension events. No new safety signals were reported.
Our results confirm the manageable safety profile of first-line bevacizumab in combination with various standard chemotherapy regimens for treatment of advanced non-squamous NSCLC.
F Hoffmann-La Roche Ltd.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancer is the leading cause of cancer-related death worldwide, with approximately 1.2 million deaths annually. The standard-of-care in patients with advanced disease is platinum-based doublet chemotherapy. Recent advances in the understanding of biological mechanisms of tumor growth have allowed for identification of some molecular targets for cancer treatment, such as vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). VEGF is a pro-angiogenetic factor, which binds membrane receptors, and whose intra-cytoplasmatic domain presents tyrosine kinase activity. Pathological angiogenesis promotes tumor growth and metastasis. Targeted action against angiogenesis can lead to regression or normalization of neovascular structures and to inhibition of new blood vessel growth. The most commonly used mechanism is mediated by bevacizumab, a monoclonal antibody that selectively binds to VEGF and prevents interaction with its receptor. Currently bevacizumab is the only anti-angiogenic agent approved for the first-line treatment of non-small cell lung cancer (NSCLC) in selected patients. In the present review, we discuss the most important trials that demonstrate the efficacy and safety of bevacizumab. We also present an overview of the types of patients eligible for this treatment and a cost-effectiveness analysis. In conclusion, the possibility of administering a treatment with bevacizumab must be carefully analyzed case by case. It is important to identify those patients who can really benefit from the use of this drug, through the identification of specific response markers.
    Anticancer research 04/2014; 34(4):1537-45. · 1.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Der Beitrag diskutiert den klinischen Stellenwert von venösen Thrombosen, arteriellen Verschlüssen und Blutungsereignissen als Folge einer antiangiogenen Therapie durch den gegen VEGF-A gerichteten monoklonalen Antikörpers Bevacizumab (BV) bei der Behandlung von Tumorerkrankungen.Selektive Literaturrecherche; Auswertung klinischer Studien.Die absoluten Zahlen für gefäßassoziierte Komplikationen wie arterielle und venöse Thromboembolien (ATE, VTE) und schwere Blutungen in Assoziation mit einer BV-haltigen Therapie sind niedrig. Die Rate an erkrankungs- und therapieassoziierten VTE ist in den untersuchten Kollektiven relativ hoch, ohne dass für BV eine klinisch relevante Risikoerhöhung für VTE nachgewiesen werden kann. Eine Antikoagulation als VTE-Prophylaxe oder Therapie kann unter Beibehaltung von BV als risikoarm angesehen werden. Daten zu den neuen direkten oralen Antikoagulanzien in Kombination mit BV liegen nicht vor. Konsistent zeigt sich eine Risikoerhöhung für ATE, dabei etwa eine Verdoppelung für kardiovaskuläre Ereignisse. Es ist davon auszugehen, dass hiervon insbesondere Patienten mit einem alterierten Gefäßsystem betroffen sind. Die Studien zeigen, dass die BV-haltige Therapie auch bei älteren Patienten (> 65 bzw. > 75 Jahre) mit arteriellen Risikofaktoren oder stattgehabter ATE zu einem Überlebensvorteil führt. Die Behandlung mit BV erhöht die Inzidenz an leichten Hämorrhagien, relevante, sehr selten auch tödliche Blutungskomplikationen können auftreten und wurden bei der Behandlung von Patienten mit NSCLC (nichtkleinzelliges Bronchialkarzinom) in Form von pulmonalen Blutungen vermehrt berichtet. Bei BV-Therapie erhöht niedrig dosiertes ASS das Blutungsrisiko nicht dysproportional, sodass bei gegebener Indikation eine Gabe von ASS und BV gerechtfertigt ist. Der Vorteil einer generellen ASS-Prophylaxe lässt sich nicht ableiten.
    Der Onkologe 11/2013; 19(11). · 0.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: With the 1997 filing of an investigational new drug application for the first agent to target angiogenesis, bevacizumab entered into phase I clinical trials and has now become a mainstay in the treatment of several cancers. Bevacizumab has changed the treatment approach for cancers due to its efficacy as well as toxicity. This article serves as a review of current efficacy data including recently published safety analyses and the direction of future pharmacodynamic evaluation to hopefully better guide its utilization.
    Therapeutic advances in drug safety. 04/2012; 3(2):59-69.

Full-text (3 Sources)

Available from
May 23, 2014